Dr. Reddy's Subsidiary Aurigene Oncology, Announced Phase 1 Results For Ribrecabtagene Autoleucel From SWASTH Study; All 8 Patients Achieved Clinical Response
Dr. Reddy's Subsidiary Aurigene Oncology, Announced Phase 1 Results For Ribrecabtagene Autoleucel From SWASTH Study; All 8 Patients Achieved Clinical Response
Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announced the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study – India's first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma. The study reported initial results from the first 8 patients. All patients were heavily pre-treated with median of 5.5 previous lines of treatment. Most patients had also received transplant in the past and had disease progression post-transplant. All 8 patients (100%) achieved clinical response, with 5/8 (62.5%) having achieved stringent complete response. With respect to safety, there were no high-grade events of Cytokine Release Syndrome (CRS) or neurotoxicity, in any of the patients.
印度雷待肯腫瘤治療有限公司，印度雷克利有限公司的全資子公司，是一家臨床階段的生物技術公司，致力於爲癌症治療引入新穎有效的治療方法，宣佈來自SWASTH研究的Ribrecabtagene autoleucel (DRL-1801)的第1期結果——印度首個針對自體BCMA導向CAR-t細胞療法的試驗，治療復發/難治性多發性骨髓瘤患者。該研究報告了頭8名患者的初始結果。所有患者都接受過多次治療，平均爲5.5種先前療法。大多數患者過去也接受過移植，並在移植後疾病進展。所有8名患者（100%）均獲得臨床反應，其中5/8（62.5%）達到嚴格的完全緩解。在安全性方面，沒有任何患者出現細胞因子釋放綜合徵（CRS）或神經毒性的高級事件。
